The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“One thing he has not done so far is to exercise and sell shsres“
Yes, have to give him that credit
@grant1987: Proven incorrect, please do elaborate?
One thing he has not done so far is to exercise and sell shsres. Which is more than can be said for the rest of the bod and senior management. Let alone the so called saviours of omega who have sold out.even after being offered the chance to buy shares at a substantial discount when the rest of us were not privy to that at that time. They could have least held on to those ones inmo.
months I have put up with your crap on this board, well no more
in the bin with computer909 spouting rubbish that's been proven incorrect numerous times
Only comments on this board and even pays £20 a month for premium rosette to make him look influential to other posters
rather stick my balls in a vice than listen to your deramping nonsense
Computer909.if the pandemic does go away faster than expected . Then cd4200 will also take off quicker together with foodtech
You have also forgotton anibody testing
Im terms of mkt cap. I would say we are at a pretty good level at the moment one large order could change this dramatically. Omega have several clients that they are in discussions with re antigen and abingdon also have a number of potential clients re antibody testing. So i would say that is quite a good position to be in. As for hmg.at least we are doing something for them. Just hope we are not supplying the boxes that say made in china.
"Not to mention keeping the underlying business going during this pandemic"
The only thing that has kept this business going in the pandemic has been the money raised in last years placing, which is a sad state of affairs for a diagnostics company when all its peers have increased their revenue many fold.
I know you look to have a soft spot for Colin, but look at his results, and now his half-truths are beginning to put him under pressure from all directions.
@upomega: with the best will in the world CD4 is not going anywhere until Covid is a distant memory, Food tech could take off but relying on china is always a risky business, they show little regards to patents and copyrights, at best the non-covid business supports an SP of 40-50p. Like it of not the fate of this company is hanging on the covid returns, and the HMG contract if we only get to phase 1, just isn't going to cut it £50M over 2 years with a margin of 18% is £4.5M profit a year, transformational when you consider it against a previous loss, but nothing to support the current mcap.
They have to sell the Visitect antigen in large numbers to make any traction, or obviously the UK pandemic roadmap falls apart and we do secure large production orders from the government.
This is purely my speculation, Visitect Antigen or bust.
I would say the ceo has covered all bases here by having a number of irons in the fire te covid productd.Not to mention keeping the underlying business going during this pandemic.
You are forgetting the rest of omegas business. Food tech about to take off in china
Let alone the u.s mkt now covid restrictions are lifting. Cd4 200 now who validated with aid agencies on standby to deploy once covid restrictions allow. Let alone further expansion of the visitect platform. T.b diagnostics testing etc.
ABDX mcap of £56M with targeted capacity of 3M a week by the end of 2021, or ODX mcap of £142M with a capacity of 1M (2M if you want to pay a commission of the second half), which acquisition looks more attractive to you ?
The only play for Omega is to secure some commercial sales outside of the HMG sh*tshow contract that Colin has got us into.
Maybe they would be interested in abingdon as well.at the end of the day omega can produce 1 milion tests per week without hmg equipment. Still a very good money spinner.
Forgot to add. The bod could . But most of their shares are now options. So inmv any offer 30 percent or above current share price would not be rejected. It probably explains as to why iis have not bought into omega.
@upomega: What exactly to you think we have that Avacta would want that they haven't already secured from ADBX and Mologic/GAD
Colin has been banging on about 2M capacity by the end of april, that is actually contracted to be end of may, and half that capacity we cant use until a government who aren't in any hurry does or doesn't ask us to produces something, even when a test is selected we could have 8-11 weeks tech transfer and still no actual orders (This imo is the £50M minimum contract value that is the equivalent of the nightingale hospital, we just standby and wait, Phase 1 of the contract.)
The DHSC may deem it allowable for us to us that equipment to manufacture for other contracts if any actually exist, but they would want a slice of that pie as well, has Colin asked for that authorisation already and does he know what the payment to the government for the use of the machines would be, i hope he has, but i very much doubt it based on previous experience.
At their current mkt cap they could use paper to acquire omega and who could block any takeover
Dream on about takeovers from that direction. AVCT's massive market cap is built on expectations they need to successfully bring at least one product to market and bank very large sales before they can think about buying anything more than a maxi pack of toilet paper.
Avactas mkt cap is now approaching 700 milion. Maybe some kind of takeover would benefit both parties. Especially with Omegas capacity . Im not sure how the rest of the business would fit in with their business though..